Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
aTyr Pharma Presents Three Posters on Efzofitimod at the American Thoracic Society (ATS) 2025 International Conference
-
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
aTyr Pharma Advances ATYR0101 to IND Candidate Stage for Pulmonary Fibrosis
-
aTyr Pharma Announces First Quarter 2025 Results and Provides Corporate Update
-
aTyr Pharma Presents Preclinical Data for NRP2-Targeting Antibody ATYR2810 at the American Association for Cancer Research (AACR) Annual Meeting 2025
-
aTyr Pharma to Participate in April Investor Conferences
-
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
aTyr Pharma Announces the Appointment of Dalia R. Rayes as Head of Commercial, Global Efzofitimod Franchise
-
aTyr Pharma Announces Fourth Quarter and Full Year 2024 Results and Provides Corporate Update
-
aTyr Pharma Announces Publication Demonstrating Efzofitimod’s Immunomodulatory Activity in Science Translational Medicine